Clinical trial

Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors

NCT04659603

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention tusamitamab ravtansine Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Gemcitabine Normalized identity: gemcitabineView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2021-03-29

PhasePHASE2

Conditions

Breast Cancer Metastaticunresolved

Pancreatic Carcinoma Metastaticunresolved

Interventions

tusamitamab ravtansineDRUG

GemcitabineDRUG · verified · RxNorm: gemcitabine

Sponsors & collaborators

Sanofilead sponsor

Mapped research locations

BostonMassachusetts, United States1 OrlandoFlorida, United States1 TaipeiTaiwan1 MoscowRussia1 BudapestHungary1 Saint PetersburgRussia1 IstanbulTurkey (Türkiye)1 MadisonWisconsin, United States1 AmsterdamNetherlands1 TaichungTaiwan1 AnkaraTurkey (Türkiye)1 TainanTaiwan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04659603 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.